ReviewTrends in cardiovascular medicine2014
An update on cardio-oncology.
Review in Trends in cardiovascular medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Changes in compliance with cardiovascular medication after a breast cancer diagnosis: a latent class trajectory analysis using French nationwide data.Breast cancer research and treatment · 2026Article
- Nicotinamide Mononucleotide Supplementation Alleviates Doxorubicin-Induced Multi-Organ Fibrosis.International journal of molecular sciences · 2024Article
- Article
- Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7.Frontiers in cardiovascular medicine · 2023Review
- Modeling Susceptibility to Cardiotoxicity in Cancer Therapy Using Human iPSC-Derived Cardiac Cells and Systems Biology.Heart failure clinics · 2022Review
- Article
- Cancer Therapies and Vascular Toxicities.Current treatment options in oncology · 2022Review
- Exercise Training for Cancer Survivors.Current treatment options in oncology · 2020Review
- Fatal heart disease among cancer patients.Nature communications · 2020Article
- Vascular Damage - Coronary Artery Disease.Journal of cardiovascular echography · 2020Review
- Common Vascular Toxicities of Cancer Therapies.Cardiology clinics · 2019Review
- Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions.Interventional cardiology (London, England) · 2019Review
- Acute coronary syndromes in patients with active hematologic malignancies - Incidence, management, and outcomes.International journal of cardiology · 2019Article
- Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors.Heart (British Cardiac Society) · 2018Review
- Building a Cardio-Onco-Hematology Program.Current oncology reports · 2018Review
- Trastuzumab in Female Breast Cancer Patients With Reduced Left Ventricular Ejection Fraction.Journal of the American Heart Association · 2018Article
- Cardiotoxicity with vascular endothelial growth factor inhibitor therapy.NPJ precision oncology · 2018Review
- Management of CAD in Patients with Active Cancer: the Interventional Cardiologists' Perspective.Current cardiology reports · 2017Review
- Ischemic Heart Disease: Special Considerations in Cardio-Oncology.Current treatment options in cardiovascular medicine · 2017Review
- Cardio-oncology: what you need to know now for clinical practice and echocardiography.Echo research and practice · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Over the past decades, there have been great advancements in the survival outcome of patients with cancer. As a consequence, treatment regimens are being extended to patient populations that would not have qualified in the past based on comorbidities and age. Furthermore, the anti-cancer regimens, which have been and are being used, can cause considerable morbidity and even mortality. In fact, new drugs such as tyrosine kinase inhibitors have yielded unanticipated side effects in frequency and severity. The cardiovascular disease spectrum is an important element in all of these. In order to optimize the outcome of cancer patients with cardiovascular diseases existing prior to cancer treatment or developing as a consequence of it, a new discipline called "cardio-oncology" has evolved over the past few years. Herein, we review the latest developments in this field including cardiotoxicities, vascular toxicities, and arrhythmias. This field is taking on more shape as cardiologists, oncologists, and hematologists are forming alliances, programs, and clinics, supported by the development of expert consensus statements on best management approaches and care of the cancer patient with cardiovascular diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.